Bempedoic Acid for Lowering LDL Cholesterol

Since the report of the first expert panel of the National Cholesterol Education Program in 1988, effectively the first contemporary professional cholesterol guidelines in the United States, lowering of low-density lipoprotein cholesterol (LDL-C) levels has been a cornerstone of atherosclerotic cardiovascular disease (ASCVD) prevention. Consistent with classical and genetic epidemiologic studies implying a causal relationship between LDL-C and ASCVD, multiple randomized clinical trials have consistently observed proportional relationships between LDL-C lowering and ASCVD risk reduction from statins. More recently, these findings have extended to nonstatin LDL-C –lowering medicines, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting monoclonal antibodies.
Source: JAMA - Category: General Medicine Source Type: research